These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22145525)

  • 21. Exceptions or alternatives to labeling requirements for products held by the Strategic National Stockpile. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2012 Feb; 77(24):5696-9. PubMed ID: 22359804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2010 Jan; ():1-31. PubMed ID: 20217914
    [No Abstract]   [Full Text] [Related]  

  • 23. First Amendment Limits on Compulsory Speech.
    Barrella N
    Food Drug Law J; 2016; 71(3):519-43. PubMed ID: 29140067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impossible? Outlawing state safety laws for generic drugs.
    Glantz LH; Annas GJ
    N Engl J Med; 2011 Aug; 365(8):681-3. PubMed ID: 21830958
    [No Abstract]   [Full Text] [Related]  

  • 25. Life after Riegel: a fresh look at medical device preemption one year after Riegel v. Medtronic, Inc.
    Wartman GJ
    Food Drug Law J; 2009; 64(2):291-311. PubMed ID: 19999286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Federal preemption of common law tort awards by the Federal Food, Drug, and Cosmetic Act.
    Carrier MK
    Food Drug Law J; 1996; 51(4):509-611. PubMed ID: 11797729
    [No Abstract]   [Full Text] [Related]  

  • 27. The future of off-label marketing regulations in the post-Sorrell era.
    Iraggi J
    Seton Hall Law Rev; 2013; 43(3):1137-63. PubMed ID: 23802338
    [No Abstract]   [Full Text] [Related]  

  • 28. The FDA, preemption, and the Supreme Court.
    Glantz LH; Annas GJ
    N Engl J Med; 2008 May; 358(18):1883-5. PubMed ID: 18450601
    [No Abstract]   [Full Text] [Related]  

  • 29. Will the Supreme Court finally eliminate ERISA preemption?
    Trueman DL
    Ann Health Law; 2004; 13(2):427-64, table of contents. PubMed ID: 15281484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Wyeth preemption case ruling sparks labeling confusion.
    Allison M
    Nat Biotechnol; 2009 May; 27(5):399-400. PubMed ID: 19430423
    [No Abstract]   [Full Text] [Related]  

  • 31. Inconsistent government policies: why FDA off-label regulation cannot survive First Amendment review under Greater New Orleans.
    Hall RF; Sobotka E
    Food Drug Law J; 2007; 62(1):1-48. PubMed ID: 17444025
    [No Abstract]   [Full Text] [Related]  

  • 32. Baby doe redux? The Department of Health and Human Services and the Born-Alive Infants Protection Act of 2002: a cautionary note on normative neonatal practice.
    Sayeed SA
    Pediatrics; 2005 Oct; 116(4):e576-85. PubMed ID: 16199687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The First Amendment and FDA restrictions on off-label uses: the call for a new approach.
    Leghorn J; Brophy E; Rother P
    Food Drug Law J; 2008; 63(2):391-406. PubMed ID: 18561466
    [No Abstract]   [Full Text] [Related]  

  • 34. Medical devices; preemption of state product liability claims--FDA. Proposed rule.
    Fed Regist; 1997 Dec; 62(239):65384-8. PubMed ID: 10176832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preemption of Non-Federal Restraints on Off-Label Product Communications.
    Chasnow J; Levitt G
    Food Drug Law J; 2016; 71(2):249-70. PubMed ID: 29140059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 37. Wyeth v Levine: implications for public health policy and practice.
    David S; Rosenbaum S
    Public Health Rep; 2010; 125(3):494-7. PubMed ID: 20433045
    [No Abstract]   [Full Text] [Related]  

  • 38. Dietary supplement labeling and advertising claims: are clinical studies on the full product required?
    Villafranco JE; Bond K
    Food Drug Law J; 2009; 64(1):43-67. PubMed ID: 19998572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients--FDA. Final rule.
    Fed Regist; 1998 Dec; 63(231):66631-72. PubMed ID: 10338880
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of Symbols in Labeling. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2016 Jun; 81(115):38911-31. PubMed ID: 27311137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.